GLP-1 Medication and Pregnancy, Breastfeeding, and Birth Control

This is one area where guessing isn't good enough, so everything below is pulled directly from the current FDA prescribing information for Wegovy and Zepbound rather than secondhand summaries. If you're of childbearing age and considering a GLP-1, these are facts worth bringing to your prescriber's attention, not assumptions to make on your own.

Planning a pregnancy: the two drugs give different timing guidance

This is a real, and often overlooked, difference between the molecules. Semaglutide's label recommends discontinuing Wegovy at least 2 months before planning to become pregnant, specifically because of semaglutide's long half-life — it stays in your system for weeks, so the label builds in a washout period to clear it before conception¹. Tirzepatide's label is different: it does not specify a pre-conception washout window, instead advising that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized². If you're actively planning a pregnancy on a timeline, this is a concrete, drug-specific fact to raise with your prescriber rather than assume is the same across molecules.

If you become pregnant while on treatment

Both labels are consistent here regardless of the pre-conception guidance: weight loss is not recommended during pregnancy, and you should discontinue the medication once pregnancy is recognized and talk to your prescriber¹². Neither label frames a pregnancy that occurs while on treatment as an emergency requiring anything beyond stopping the drug and following up with your OB and prescriber.

Breastfeeding

Guidance differs by formulation, so check which one applies to you. For Zepbound (tirzepatide) injection, a lactation study found tirzepatide concentrations in breast milk were undetectable or low relative to the maternal dose, and the label frames this as a risk-benefit conversation between the benefits of breastfeeding and your clinical need for the medication, rather than a flat prohibition². For Wegovy (semaglutide), the injectable formulation carries similar risk-benefit framing, but the oral tablet formulation is different: breastfeeding is not recommended during treatment with the Wegovy tablet specifically, due to a tablet-specific absorption-enhancer ingredient (SNAC) and its potential presence in breast milk — a caution that does not apply to the injectable form, which contains no SNAC¹. Which formulation you're on changes the answer, so this is worth confirming directly rather than assuming.

The birth control interaction — this one is concrete and actionable

Here's a specific, practical safety fact that's easy to miss: tirzepatide (Zepbound and Mounjaro) delays gastric emptying, and the label explicitly warns this can reduce the absorption — and therefore the effectiveness — of oral hormonal contraceptives². The label's specific advice is to switch to a non-oral contraceptive method, or add a barrier method (like condoms) for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase². A broader 2025 pharmacology review of GLP-1 and GIP/GLP-1 drug interactions confirms this delayed-gastric-emptying mechanism as a real, class-relevant consideration for orally absorbed medications generally, not just birth control³. If you rely on an oral contraceptive pill and are starting or increasing your dose of a tirzepatide-based medication, this is not optional fine print — an unintended pregnancy risk from reduced pill absorption during dose escalation is a real, documented mechanism, not a theoretical one.

What to actually do with this information

Tell your prescriber directly if you are pregnant, trying to become pregnant on any timeline, breastfeeding, or relying on an oral contraceptive — don't assume it will come up unprompted in a fast telehealth intake. A provider with real clinician review, not just an automated questionnaire, is more likely to catch and discuss timing-specific guidance like the semaglutide washout period or the tirzepatide contraceptive interaction; see how to choose a GLP-1 provider for what that oversight should look like in practice, and our broader rundown of side effects and how to manage them for other safety considerations worth raising early.

The bottom line: semaglutide asks for a 2-month washout before a planned pregnancy due to its long half-life; tirzepatide's label instead says to stop when pregnancy is recognized; breastfeeding guidance depends on the specific formulation; and tirzepatide can measurably reduce how well oral birth control works during dose escalation, with a documented 4-week backup-contraception window. These are label facts, not internet rumors — bring them to your prescriber.